EGFR and non-small cell lung carcinoma: Given its mechanisms of action and the prerequisite of ATP hydrolysis for EGFR catalytic activity, erlotinib was predicted to elicit a positive drug response in patients with NSCLC as long as they were positive for EGFR expression, regardless of the EGFR mutation status.